WO2010125102A1 - 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS - Google Patents
5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS Download PDFInfo
- Publication number
- WO2010125102A1 WO2010125102A1 PCT/EP2010/055715 EP2010055715W WO2010125102A1 WO 2010125102 A1 WO2010125102 A1 WO 2010125102A1 EP 2010055715 W EP2010055715 W EP 2010055715W WO 2010125102 A1 WO2010125102 A1 WO 2010125102A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbonyl
- triazolo
- tetrahydro
- pyrazine
- chloro
- Prior art date
Links
- 0 Cc1c(*)[s]c(*)n1 Chemical compound Cc1c(*)[s]c(*)n1 0.000 description 16
- SVTCMUVJFZIAQG-UHFFFAOYSA-N C1NCc2nnc(-c3ncn[s]3)[n]2C1 Chemical compound C1NCc2nnc(-c3ncn[s]3)[n]2C1 SVTCMUVJFZIAQG-UHFFFAOYSA-N 0.000 description 1
- VCRYEKGTKXZJLD-UHFFFAOYSA-N CC(C)(C)OC(NNC(c1ccn[o]1)=O)=O Chemical compound CC(C)(C)OC(NNC(c1ccn[o]1)=O)=O VCRYEKGTKXZJLD-UHFFFAOYSA-N 0.000 description 1
- GMYSOLGTHYNLBA-UHFFFAOYSA-N CC(C)(C)OC(NNC(c1ncc(C)[s]1)=O)=O Chemical compound CC(C)(C)OC(NNC(c1ncc(C)[s]1)=O)=O GMYSOLGTHYNLBA-UHFFFAOYSA-N 0.000 description 1
- GSEANZFIQZDNBT-UHFFFAOYSA-N CCOC(C(NC=O)=S)=O Chemical compound CCOC(C(NC=O)=S)=O GSEANZFIQZDNBT-UHFFFAOYSA-N 0.000 description 1
- KYAATGSGTLPBHN-UHFFFAOYSA-N Cc(c(Cl)ccc1C(O)=O)c1Cl Chemical compound Cc(c(Cl)ccc1C(O)=O)c1Cl KYAATGSGTLPBHN-UHFFFAOYSA-N 0.000 description 1
- RPFSZXNACGKXQI-UHFFFAOYSA-N Cc1c(-c2nnc(C3)[n]2CCN3C(c(c(Cl)c2F)ccc2Cl)=O)[s]nn1 Chemical compound Cc1c(-c2nnc(C3)[n]2CCN3C(c(c(Cl)c2F)ccc2Cl)=O)[s]nn1 RPFSZXNACGKXQI-UHFFFAOYSA-N 0.000 description 1
- LXCQZNYXNOLHEU-UHFFFAOYSA-N Cc1c(-c2nnc(C3)[n]2CCN3C(c2cccc(Cl)c2C)=O)nc[s]1 Chemical compound Cc1c(-c2nnc(C3)[n]2CCN3C(c2cccc(Cl)c2C)=O)nc[s]1 LXCQZNYXNOLHEU-UHFFFAOYSA-N 0.000 description 1
- VHVHOUZISABZCA-UHFFFAOYSA-N Cc1c(C(NN)=O)nc[s]1 Chemical compound Cc1c(C(NN)=O)nc[s]1 VHVHOUZISABZCA-UHFFFAOYSA-N 0.000 description 1
- GKMDPPXBCLAACF-UHFFFAOYSA-N Cc1ccc(C(NN)=O)[o]1 Chemical compound Cc1ccc(C(NN)=O)[o]1 GKMDPPXBCLAACF-UHFFFAOYSA-N 0.000 description 1
- KVZUULWDZYNNCC-UHFFFAOYSA-N N#Cc(c(Cl)ccc1)c1C(O)=O Chemical compound N#Cc(c(Cl)ccc1)c1C(O)=O KVZUULWDZYNNCC-UHFFFAOYSA-N 0.000 description 1
- ZOBLHYIDECUIHB-UHFFFAOYSA-N O=C(c(c(Cl)c1)ccc1Cl)N1Cc2nnc(-c3nccnc3)[n]2CC1 Chemical compound O=C(c(c(Cl)c1)ccc1Cl)N1Cc2nnc(-c3nccnc3)[n]2CC1 ZOBLHYIDECUIHB-UHFFFAOYSA-N 0.000 description 1
- VOZZHBAHNGPQEW-UHFFFAOYSA-N O=C(c(c(Cl)c1Cl)ccc1F)N1Cc2nnc(-c3cnccn3)[n]2CC1 Chemical compound O=C(c(c(Cl)c1Cl)ccc1F)N1Cc2nnc(-c3cnccn3)[n]2CC1 VOZZHBAHNGPQEW-UHFFFAOYSA-N 0.000 description 1
- OLVQLATWVXFLMA-UHFFFAOYSA-N O=C(c(c(Cl)c1Cl)ccc1F)N1Cc2nnc(-c3nnccc3)[n]2CC1 Chemical compound O=C(c(c(Cl)c1Cl)ccc1F)N1Cc2nnc(-c3nnccc3)[n]2CC1 OLVQLATWVXFLMA-UHFFFAOYSA-N 0.000 description 1
- VKWACVOIMKCRJZ-UHFFFAOYSA-N O=C(c(c(Cl)c1F)ccc1Cl)N1Cc2nnc(-c3ccn[s]3)[n]2CC1 Chemical compound O=C(c(c(Cl)c1F)ccc1Cl)N1Cc2nnc(-c3ccn[s]3)[n]2CC1 VKWACVOIMKCRJZ-UHFFFAOYSA-N 0.000 description 1
- INKWKJKHJJUEDX-UHFFFAOYSA-N O=C(c(cc1)cc(Cl)c1Cl)N1Cc2nnc(-c3cnccn3)[n]2CC1 Chemical compound O=C(c(cc1)cc(Cl)c1Cl)N1Cc2nnc(-c3cnccn3)[n]2CC1 INKWKJKHJJUEDX-UHFFFAOYSA-N 0.000 description 1
- GGTVCXZYJSLSKH-UHFFFAOYSA-N O=C(c(cccc1C(F)(F)F)c1Cl)N(CC[n]12)Cc1nnc2N1CCOCC1 Chemical compound O=C(c(cccc1C(F)(F)F)c1Cl)N(CC[n]12)Cc1nnc2N1CCOCC1 GGTVCXZYJSLSKH-UHFFFAOYSA-N 0.000 description 1
- XDVOAXOJEKZACL-UHFFFAOYSA-N O=C(c1cccc(Cl)c1Cl)N1Cc2nnc(-c3c[s]cn3)[n]2CC1 Chemical compound O=C(c1cccc(Cl)c1Cl)N1Cc2nnc(-c3c[s]cn3)[n]2CC1 XDVOAXOJEKZACL-UHFFFAOYSA-N 0.000 description 1
- YVMOGMYTHGGMHP-UHFFFAOYSA-N O=C(c1cccc(Cl)c1Cl)N1Cc2nnc(-c3ncc[s]3)[n]2CC1 Chemical compound O=C(c1cccc(Cl)c1Cl)N1Cc2nnc(-c3ncc[s]3)[n]2CC1 YVMOGMYTHGGMHP-UHFFFAOYSA-N 0.000 description 1
- KPFXMYOQAANDKH-UHFFFAOYSA-N OC(c(c(Cl)c1Cl)ccc1F)=O Chemical compound OC(c(c(Cl)c1Cl)ccc1F)=O KPFXMYOQAANDKH-UHFFFAOYSA-N 0.000 description 1
- GIKLUFKGUFDHBZ-UHFFFAOYSA-N Oc1ncccc1-c1nnc(C2)[n]1CCN2C(c(ccc(Cl)c1F)c1Cl)=O Chemical compound Oc1ncccc1-c1nnc(C2)[n]1CCN2C(c(ccc(Cl)c1F)c1Cl)=O GIKLUFKGUFDHBZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/266,592 US8501946B2 (en) | 2009-04-29 | 2010-04-28 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators |
EP10720006.5A EP2424869B1 (en) | 2009-04-29 | 2010-04-28 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
JP2012507732A JP5654001B2 (ja) | 2009-04-29 | 2010-04-28 | P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体 |
ES10720006.5T ES2590987T3 (es) | 2009-04-29 | 2010-04-28 | Derivados de 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina como moduladores de P2X7 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17370109P | 2009-04-29 | 2009-04-29 | |
US61/173,701 | 2009-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010125102A1 true WO2010125102A1 (en) | 2010-11-04 |
Family
ID=42289654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/055715 WO2010125102A1 (en) | 2009-04-29 | 2010-04-28 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
Country Status (5)
Country | Link |
---|---|
US (1) | US8501946B2 (ja) |
EP (1) | EP2424869B1 (ja) |
JP (1) | JP5654001B2 (ja) |
ES (1) | ES2590987T3 (ja) |
WO (1) | WO2010125102A1 (ja) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011033055A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Fused triazole amines as p2x7 modulators |
US20120157436A1 (en) * | 2009-04-29 | 2012-06-21 | David Kenneth Dean | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
JP2012525351A (ja) * | 2009-04-30 | 2012-10-22 | グラクソ グループ リミテッド | P2X7調節因子としての5,6,7,8−テトラヒドロイミダゾ[1,2−a]ピラジン誘導体 |
WO2013050424A1 (en) * | 2011-10-03 | 2013-04-11 | Euroscreen S.A. | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF |
EP2604265A1 (en) | 2011-12-17 | 2013-06-19 | Royal College of Surgeons in Ireland (RCSI) | P2x7 antagonists as frontline or adjunctive treatment against status epilepticus |
WO2014152621A1 (en) * | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
WO2014152537A1 (en) * | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
WO2014154897A1 (en) * | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
WO2014154896A1 (en) * | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
WO2014154895A1 (en) | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
US8871761B2 (en) | 2010-04-02 | 2014-10-28 | Euroscreen S.A. | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
WO2016039977A1 (en) * | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
WO2016039983A1 (en) * | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulating n-acyl-triazolopyrazines |
WO2016046398A1 (en) * | 2014-09-25 | 2016-03-31 | Euroscreen Sa | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines |
US9464084B2 (en) | 2013-03-14 | 2016-10-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
US10292970B2 (en) | 2014-12-02 | 2019-05-21 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use |
WO2020211798A1 (zh) * | 2019-04-16 | 2020-10-22 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
US11066409B2 (en) | 2016-10-17 | 2021-07-20 | Shionogi & Co., Ltd. | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same |
US11124486B2 (en) | 2015-04-24 | 2021-09-21 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
CN113527307A (zh) * | 2020-04-20 | 2021-10-22 | 上海翰森生物医药科技有限公司 | 含三唑基的并环类衍生物抑制剂、其制备方法和应用 |
CN113549074A (zh) * | 2020-04-26 | 2021-10-26 | 上海翰森生物医药科技有限公司 | 含三唑基的并环类衍生物抑制剂、其制备方法和应用 |
US11597728B2 (en) | 2018-09-28 | 2023-03-07 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
US11820766B2 (en) | 2018-09-28 | 2023-11-21 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
US11839663B2 (en) | 2019-09-30 | 2023-12-12 | Janssen Pharmaceutica Nv | Radiolabelled MGL pet ligands |
US11891387B2 (en) | 2020-03-26 | 2024-02-06 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014195321A1 (en) * | 2013-06-04 | 2014-12-11 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
EP3496716B1 (en) | 2016-08-15 | 2021-11-03 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
WO2018034917A1 (en) * | 2016-08-15 | 2018-02-22 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
WO2019145214A1 (en) * | 2018-01-26 | 2019-08-01 | Recordati Industria Chimica E Farmaceutica S.P.A | TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008124153A1 (en) * | 2007-04-10 | 2008-10-16 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
WO2009027730A1 (en) * | 2007-08-24 | 2009-03-05 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0518237D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
JP5654001B2 (ja) * | 2009-04-29 | 2015-01-14 | グラクソ グループ リミテッドGlaxo Group Limited | P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体 |
BR112012025101B1 (pt) * | 2010-04-02 | 2021-08-31 | Ogeda S.A. | Compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e medicamento compreendendo os mesmos |
-
2010
- 2010-04-28 JP JP2012507732A patent/JP5654001B2/ja active Active
- 2010-04-28 EP EP10720006.5A patent/EP2424869B1/en active Active
- 2010-04-28 ES ES10720006.5T patent/ES2590987T3/es active Active
- 2010-04-28 WO PCT/EP2010/055715 patent/WO2010125102A1/en active Application Filing
- 2010-04-28 US US13/266,592 patent/US8501946B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008124153A1 (en) * | 2007-04-10 | 2008-10-16 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
WO2009027730A1 (en) * | 2007-08-24 | 2009-03-05 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
Non-Patent Citations (14)
Title |
---|
ANDERSON, C. ET AL., DRUG. DEV. RES., vol. 50, 2000, pages 92 |
BERGE; BIGHLEY; MONKHOUSE, J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
CHESSELL, IP. ET AL., PAIN, vol. 114, 2005, pages 386 - 396 |
COLLO ET AL., NEUROPHARMACOLOGY, vol. 36, 1997, pages 1277 - 1283 |
DELL'ANTONIO ET AL., NEUROSCI. LETT., vol. 327, 2002, pages 87 - 90 |
EUR. J. ORG.CHEM., 2006, pages 4398 - 4404 |
FERRARI ET AL., J. IMMUNOL., vol. 176, 2006, pages 3877 - 3883 |
HIDE ET AL., JOURNAL OF NEUROCHEMISTRY, vol. 75, 2000, pages 965 - 972 |
HONORE ET AL., J. PHARMACOL. EXP. THER., vol. 319, 2006, pages 1376 - 1385 |
J. ORG. CHEM., vol. 68, no. 5, 2003, pages 2030 - 2033 |
J.MED.CHEM., vol. 39, no. 20, 1996, pages 436 - 445 |
K.C. CUNDY ET AL.: "Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin", J. CLIN. PHARMACOL., 30 September 2008 (2008-09-30), XP000013512 |
PARVATHENANI, L. ET AL., J. BIOL. CHEM., vol. 278, no. 15, 2003, pages 13309 - 13317 |
SKAPER, S.D. ET AL., GLIA, vol. 54, 2006, pages 234 - 242 |
Cited By (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501946B2 (en) * | 2009-04-29 | 2013-08-06 | Glaxo Group Limited | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators |
US20120157436A1 (en) * | 2009-04-29 | 2012-06-21 | David Kenneth Dean | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
JP2012525351A (ja) * | 2009-04-30 | 2012-10-22 | グラクソ グループ リミテッド | P2X7調節因子としての5,6,7,8−テトラヒドロイミダゾ[1,2−a]ピラジン誘導体 |
WO2011033055A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Fused triazole amines as p2x7 modulators |
US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
US9926325B2 (en) | 2010-04-02 | 2018-03-27 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
US10544150B2 (en) | 2010-04-02 | 2020-01-28 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
US8871761B2 (en) | 2010-04-02 | 2014-10-28 | Euroscreen S.A. | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
AU2012320568C1 (en) * | 2011-10-03 | 2018-07-19 | Ogeda S.A. | Novel chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof |
WO2013050424A1 (en) * | 2011-10-03 | 2013-04-11 | Euroscreen S.A. | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF |
EA029340B1 (ru) * | 2011-10-03 | 2018-03-30 | Огеда Са | ХИРАЛЬНЫЕ N-АЦИЛ-5,6,7,(8-ЗАМЕЩЕННЫЕ)-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПРИМЕНЕНИЯ ПРИ НАРУШЕНИЯХ, ОПОСРЕДОВАННЫХ NK-3 РЕЦЕПТОРАМИ, И ИХ ХИРАЛЬНЫЙ СИНТЕЗ |
US10941151B2 (en) | 2011-10-03 | 2021-03-09 | Ogeda Sa | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof |
CN103906750A (zh) * | 2011-10-03 | 2014-07-02 | 欧洲筛选有限公司 | 作为选择性NK-3受体拮抗剂的新型手性N-酰基-5,6,7,(8-取代的)-四氢-[1,2,4]三唑并[4,3-a]吡嗪、药物组合物、用于NK-3受体介导的疾病中的方法及其手性合成 |
US10065961B2 (en) | 2011-10-03 | 2018-09-04 | Ogeda Sa. | Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof |
EP3029042A1 (en) * | 2011-10-03 | 2016-06-08 | Euroscreen S.A. | Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor mediated disorders and chiral synthesis thereof |
AU2012320568B2 (en) * | 2011-10-03 | 2017-07-06 | Ogeda S.A. | Novel chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof |
US10683295B2 (en) | 2011-10-03 | 2020-06-16 | Ogeda Sa | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof |
US9475814B2 (en) | 2011-10-03 | 2016-10-25 | Euroscreen S.A. | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof |
WO2013087943A1 (en) | 2011-12-17 | 2013-06-20 | Royal College Of Surgeons In Ireland (Rcsi) | P2x7 antagonists as frontline or adjunctive treatment against status epilepticus |
EP2604265A1 (en) | 2011-12-17 | 2013-06-19 | Royal College of Surgeons in Ireland (RCSI) | P2x7 antagonists as frontline or adjunctive treatment against status epilepticus |
WO2014152537A1 (en) * | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
JP2016513698A (ja) * | 2013-03-14 | 2016-05-16 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7モジュレーター |
US10150765B2 (en) | 2013-03-14 | 2018-12-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
US9464084B2 (en) | 2013-03-14 | 2016-10-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
US10323032B2 (en) | 2013-03-14 | 2019-06-18 | Janssen Pharmaceutica Nv | P2X7 Modulators |
US9540388B2 (en) | 2013-03-14 | 2017-01-10 | Janssen Pharmaceutica Nv | P2X7 modulators |
US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
US10112937B2 (en) | 2013-03-14 | 2018-10-30 | Janssen Pharmaceutica Nv | P2X7 modulators and methods of use |
US10703749B2 (en) | 2013-03-14 | 2020-07-07 | Janssen Pharmaceutica Nv | P2X7 modulators |
US9102686B2 (en) | 2013-03-14 | 2015-08-11 | Janssen Pharmaceutica Nv | 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators |
US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
US10053462B2 (en) | 2013-03-14 | 2018-08-21 | Janssen Pharmaceutica Nv | P2X7 modulators |
US10053463B2 (en) | 2013-03-14 | 2018-08-21 | Janssen Pharmaceutica Nv | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
US10047092B2 (en) | 2013-03-14 | 2018-08-14 | Janssen Pharmaceutica Nv | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
US11225478B2 (en) | 2013-03-14 | 2022-01-18 | Janssen Pharmaceutica Nv | P2X7 modulators |
US11820770B2 (en) | 2013-03-14 | 2023-11-21 | Janssen Pharmaceutica Nv | P2X7 modulators |
WO2014152621A1 (en) * | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
EP3309161A1 (en) * | 2013-03-14 | 2018-04-18 | Janssen Pharmaceutica NV | P2x7 modulators |
TWI627174B (zh) * | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | P2x7調控劑 |
US9969738B2 (en) | 2013-03-29 | 2018-05-15 | Ogeda Sa | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
EA027570B1 (ru) * | 2013-03-29 | 2017-08-31 | Огеда Са | НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО-[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ, ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3 |
US9969745B2 (en) | 2013-03-29 | 2018-05-15 | Ogeda Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
CN105229008B (zh) * | 2013-03-29 | 2017-12-15 | 欧歌达有限公司 | 作为选择性NK‑3受体拮抗剂的N‑酰基‑(3‑取代)‑(8‑取代)‑5,6‑二氢‑[1,2,4]三唑并[4,3‑a]吡嗪、药物组合物、用于NK‑3受体介导的病症的方法 |
AU2014242908B2 (en) * | 2013-03-29 | 2018-07-19 | Ogeda Sa | Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
US10030025B2 (en) | 2013-03-29 | 2018-07-24 | Ogeda Sa | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
US9840508B2 (en) | 2013-03-29 | 2017-12-12 | Oged Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
US10836768B2 (en) | 2013-03-29 | 2020-11-17 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
EP3219715A1 (en) | 2013-03-29 | 2017-09-20 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
WO2014154895A1 (en) | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
WO2014154897A1 (en) * | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
CN105229008A (zh) * | 2013-03-29 | 2016-01-06 | 欧洲筛选有限公司 | 作为选择性NK-3受体拮抗剂的新型N-酰基-(3-取代)-(8-取代)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪、药物组合物、用于NK-3受体介导的病症的方法 |
US9987274B2 (en) | 2013-03-29 | 2018-06-05 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
US9422299B2 (en) | 2013-03-29 | 2016-08-23 | Euroscreen Sa | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
US10214533B2 (en) | 2013-03-29 | 2019-02-26 | Ogeda Sa | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
US11731974B2 (en) | 2013-03-29 | 2023-08-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
WO2014154896A1 (en) * | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
AU2015315687B2 (en) * | 2014-09-12 | 2019-07-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
EA034015B1 (ru) * | 2014-09-12 | 2019-12-19 | Янссен Фармацевтика Нв | Модуляторы р2х7 |
US10150766B2 (en) | 2014-09-12 | 2018-12-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
WO2016039983A1 (en) * | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulating n-acyl-triazolopyrazines |
WO2016039977A1 (en) * | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
CN107001289B (zh) * | 2014-09-25 | 2019-12-31 | 欧歌达有限公司 | N-酰基-(3-取代的)-(8-取代的)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪的新手性合成 |
EA032052B1 (ru) * | 2014-09-25 | 2019-03-29 | Огеда Са | СПОСОБ ХИРАЛЬНОГО СИНТЕЗА N-АЦИЛ-(3-ЗАМЕЩЕННЫХ)-(8-ЗАМЕЩЕННЫХ)-5,6-ДИГИДРО-[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНОВ |
US10787458B2 (en) | 2014-09-25 | 2020-09-29 | Ogeda Sa | Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines |
CN107001289A (zh) * | 2014-09-25 | 2017-08-01 | 欧歌达有限公司 | N‑酰基‑(3‑取代的)‑(8‑取代的)‑5,6‑二氢‑[1,2,4]三唑并[4,3‑a]吡嗪的新手性合成 |
WO2016046398A1 (en) * | 2014-09-25 | 2016-03-31 | Euroscreen Sa | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines |
US10292970B2 (en) | 2014-12-02 | 2019-05-21 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use |
US11124486B2 (en) | 2015-04-24 | 2021-09-21 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
US11685740B2 (en) | 2016-10-17 | 2023-06-27 | Shionogi & Co., Ltd. | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same |
US11066409B2 (en) | 2016-10-17 | 2021-07-20 | Shionogi & Co., Ltd. | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same |
US11597728B2 (en) | 2018-09-28 | 2023-03-07 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
US11820766B2 (en) | 2018-09-28 | 2023-11-21 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
WO2020211798A1 (zh) * | 2019-04-16 | 2020-10-22 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
CN112272670A (zh) * | 2019-04-16 | 2021-01-26 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
CN112272670B (zh) * | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
US11839663B2 (en) | 2019-09-30 | 2023-12-12 | Janssen Pharmaceutica Nv | Radiolabelled MGL pet ligands |
US11891387B2 (en) | 2020-03-26 | 2024-02-06 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
CN113527307A (zh) * | 2020-04-20 | 2021-10-22 | 上海翰森生物医药科技有限公司 | 含三唑基的并环类衍生物抑制剂、其制备方法和应用 |
CN113549074A (zh) * | 2020-04-26 | 2021-10-26 | 上海翰森生物医药科技有限公司 | 含三唑基的并环类衍生物抑制剂、其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
JP5654001B2 (ja) | 2015-01-14 |
EP2424869A1 (en) | 2012-03-07 |
EP2424869B1 (en) | 2016-06-22 |
US20120157436A1 (en) | 2012-06-21 |
ES2590987T3 (es) | 2016-11-24 |
US8501946B2 (en) | 2013-08-06 |
JP2012525352A (ja) | 2012-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2424869B1 (en) | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | |
EP2424867B1 (en) | 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine derivatives as p2x7 modulators | |
EP2155685B1 (en) | Pyrazole derivatives as p2x7 modulators | |
KR101585753B1 (ko) | 브루톤 티로신 키나아제의 억제제 | |
JP5485178B2 (ja) | ピロロピラジンキナーゼ阻害剤 | |
JP5284377B2 (ja) | ピロロピラジンキナーゼ阻害剤 | |
US8962596B2 (en) | 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases | |
JP6109192B2 (ja) | ピリダジンアミド化合物及びsyk阻害剤としてのそれらの使用 | |
KR101077806B1 (ko) | 신규 피페라진 화합물, 및 hcv 중합효소 억제제로서의 그의 용도 | |
MX2012013194A (es) | Derivados pirrolopirazinas como inhibidores de cinasas tirocina-cinasa del baso (syk) y cinasa de janus (jak). | |
JP2013522334A (ja) | ピロロピラジンのキナーゼ阻害剤 | |
JP5667692B2 (ja) | ピロロピラジン誘導体とjak及びsyk阻害剤としてのその使用 | |
AU2007235487A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
PT2250172E (pt) | Inibidores de pirrolpirazina-cinase | |
JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
WO2017046737A1 (en) | 1-phenylpyrrolidin-2-one derivatives as perk inhibitors | |
JP4109890B2 (ja) | 医薬組成物 | |
ES2369826T3 (es) | Inhibidores de quinasas de pirrolopirazina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10720006 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012507732 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010720006 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13266592 Country of ref document: US |